Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$102,581 Mln
Revenue (TTM)
$20,074 Mln
Net Profit (TTM)
$2,886 Mln
ROE
0.1 %
ROCE
8.3 %
P/E Ratio
35.6
P/B Ratio
4.2
Industry P/E
--
EV/EBITDA
21.8
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$16.2
EPS
$1.9
Face value
--
Shares outstanding
1,483,885,456
CFO
$13,820.00 Mln
EBITDA
$22,128.00 Mln
Net Profit
$10,042.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Boston Scientific Corp (BSX)
| -25.2 | -6.6 | -24.6 | -27.9 | 14.1 | 12.9 | 14.8 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Boston Scientific Corp (BSX)
| 6.8 | 54.0 | 24.9 | 8.9 | 18.2 | -20.5 | 28.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Boston Scientific Corp (BSX)
|
71.3 | 102,581.0 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 35.6 | 4.2 |
| 108.5 | 187,721.9 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 29 | 3.6 | |
| 158.1 | 57,735.4 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 26 | 1.8 | |
| 191.5 | 132,461.4 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.2 | 2.9 | |
| 82.6 | 47,515.3 | 6,067.6 | 1,073.5 | 20.4 | 10.6 | 45.2 | 4.8 | |
| 577.1 | 45,820.3 | 4,303.7 | 1,059.5 | 31.7 | 66.2 | 43.9 | 28.5 | |
| 477.7 | 167,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 227.9 | 33,694.9 | 5,398.1 | 1,485.9 | 34.0 | 24.2 | 22.8 | 5.3 | |
| 345.8 | 128,878.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40.1 | 5.8 | |
| 464.7 | 172,506.1 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.2 | 3.3 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and... treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. Read more
Chairman, President & CEO
Mr. Michael F. Mahoney
Chairman, President & CEO
Mr. Michael F. Mahoney
Headquarters
Marlborough, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Boston Scientific Corp (BSX) is $71.28 (NYSE) as of 18-Mar-2026 16:28 EDT. Boston Scientific Corp (BSX) has given a return of 14.13% in the last 3 years.
The P/E ratio of Boston Scientific Corp (BSX) is 35.63 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
49.42
|
5.89
|
|
2024
|
71.79
|
6.11
|
|
2023
|
53.60
|
4.43
|
|
2022
|
95.62
|
3.80
|
|
2021
|
58.66
|
3.67
|
The 52-week high and low of Boston Scientific Corp (BSX) are Rs 109.50 and Rs 67.56 as of 19-Mar-2026.
Boston Scientific Corp (BSX) has a market capitalisation of $ 102,581 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Boston Scientific Corp (BSX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.08
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.